Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Fewer people successfully treated with trichloroacetic acid experienced recurrence.
Topical treatment may be as effective as electrocautery for anal neoplasia but with fewer adverse effects.
Treatments that help the immune system fight cancer have revolutionized cancer care.
LGBTQ disparities exist in cervical cancer prevention—including HPV vaccines—and in rates of anal cancer, notably among those with HIV.
Human papillomavirus and hepatitis B vaccines lower the risk of developing cancer.
Human papillomavirus, a common sexually transmitted infection, can cause cervical, anal, and oral cancers.
Vaccines could potentially eliminate cervical, anal, oral and other cancers caused by human papillomavirus.
Screening for abnormal anal cell changes and treating them early can reduce the risk of progression to anal cancer in people with HIV.
A pilot program is assessing whether self-testing for the cancer-causing virus can reach women who otherwise might not get screened.
Prompt treatment of precancerous lesions in people with HIV reduced the likelihood of developing anal cancer by 57%.
Treating abnormal anal cell changes early can reduce the risk of progression to anal cancer in people living with HIV.
Long-awaited results from the ANCHOR study suggest screening to detect precancerous lesions should be part of routine care.
A majority people with oral and throat cancer tested positive for DNA from high-risk HPV types in their saliva.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.